STM JOURNALS

Trends in
Drug Delivery

https://journals.stmjournals.com/tdd

ISSN: 2394-7268
Volume 12, Issue 2, 2025
May–August
DOI (Journal): 10.37591/TDD

Review TDD

Ocular Films as a Drug Delivery System Against Fungal Infections: Current Insights and Future Directions

Keshav Rao Bapu Rao Kulkarni[1], Satish Kumar Sarankar[2,*]

Abstract

Fungal infections of the eye, including keratitis, endophthalmitis, and blepharitis, represent a challenging class of ocular diseases due to their potential for vision loss and the limited efficacy of existing treatments. These infections are caused by a range of pathogenic fungi, such as Aspergillus, Candida, and Fusarium species, and often require long-term therapeutic intervention. Conventional topical antifungal therapies, such as eye drops and ointments, suffer from poor ocular bioavailability due to rapid tear drainage, blinking, and limited corneal permeability. These limitations often necessitate frequent dosing and may lead to suboptimal therapeutic outcomes. In recent years, ocular films have emerged as an innovative and promising alternative for ocular drug delivery. These thin, polymer-based inserts adhere to the ocular surface and allow for controlled and sustained release of antifungal agents directly at the site of infection. They offer several advantages over traditional formulations, including prolonged retention time, improved patient compliance, reduced dosing frequency, and enhanced drug stability. Moreover, ocular films can be designed using a variety of polymers and fabrication methods to tailor their drug release profile, mucoadhesive properties, and biodegradability. This review provides an in-depth analysis of the pathophysiology and epidemiology of ocular fungal infections, emphasizing the need for more effective localized therapies. It explores the limitations of current delivery systems and highlights the superior design flexibility and performance of ocular films. The mechanisms of drug release, including diffusion-controlled and swelling-mediated systems, are also reviewed, alongside film retention strategies like mucoadhesion and bioresorption. Despite their potential, several scientific challenges remain in the widespread adoption of ocular films. These include issues related to drug loading capacity, polymer compatibility, manufacturing scalability, and individual variability in ocular physiology. The review concludes by outlining prospects, including smart, stimuli-responsive ocular films, and the integration of nanotechnology and biosensors for precision drug delivery. By addressing these challenges through multidisciplinary research, ocular films could revolutionize the management of ocular fungal infections and serve as a platform for treating a broader range of ocular diseases in the future.

Keywords: Ocular fungal infections, ocular drug delivery, polymeric ocular films, antifungal therapy, sustained release systems

***Author for Correspondence**
Satish Kumar Sarankar
E-Mail: satish.sarankar@gmail.com

[1]Research Scholar, Department of Pharmacy, Mansarovar Global University, Sehore, Madhya Pradesh, India.
[2]Professor & Principal, Department of Pharmacy, Mansarovar Global University, Sehore, Madhya Pradesh, India.

Received Date: April 25, 2025
Accepted Date: June 02, 2025
Published Date: June 20, 2025

Citation: Keshav Rao Bapu Rao Kulkarni, Satish Kumar Sarankar. Ocular Films as a Drug Delivery System Against Fungal Infections: Current Insights and Future Directions. Trends in Drug Delivery: 2025; 12(2): 101–109p.

INTRODUCTION

The human eye is a highly sensitive organ that requires precise and effective therapeutic approaches to combat infections. Ocular fungal infections, although less common than bacterial or viral infections, are often more difficult to treat and may result in severe consequences, including blindness. The structure of the eye, particularly its protective barriers, such as the corneal epithelium and the blood-ocular barrier, poses a significant challenge for effective drug delivery. These anatomical and physiological barriers restrict the penetration of therapeutic agents, necessitating

frequent administration of high drug doses to achieve the desired therapeutic effect [1]. Traditional ocular drug delivery methods, including eye drops and ointments, are hindered by poor retention time and rapid clearance through the nasolacrimal drainage system. As a result, these treatments often fail to maintain adequate drug concentrations at the site of infection, leading to suboptimal therapeutic outcomes and the risk of disease progression [2]. Furthermore, the emergence of antifungal resistance, especially among Candida and Fusarium species, adds complexity to the treatment regimen, emphasizing the need for localized and sustained drug delivery systems. Recent advancements in pharmaceutical technology have introduced various novel drug delivery platforms aimed at enhancing drug bioavailability and residence time in the ocular cavity. Among these, ocular films have garnered significant attention due to their ability to provide targeted, controlled, and sustained release of antifungal agents directly to the ocular tissues. These films are designed to adhere to the ocular surface, resist tear dilution, and gradually release the drug, thereby minimizing dosing frequency and improving patient compliance.

Ocular films can be engineered using a wide range of polymers and excipients, allowing for customization of drug release profiles and mechanical properties. Their versatility enables the incorporation of both hydrophilic and lipophilic drugs, expanding their potential applications in ocular therapeutics. Additionally, advancements in nanotechnology and polymer science have facilitated the development of hybrid ocular film systems that can respond to environmental stimuli, further enhancing drug delivery efficiency [3]. In this context, the present review aims to provide a comprehensive analysis of the role of ocular films as a novel drug delivery system for the treatment of fungal eye infections. The review delves into the pathophysiology and epidemiology of ocular fungal diseases, the limitations of conventional treatments, and the design, formulation, and evaluation of ocular films loaded with antifungal agents. The challenges and prospects of this innovative drug delivery approach are also discussed to offer insights into its translational potential.

PATHOPHYSIOLOGY AND EPIDEMIOLOGY OF OCULAR FUNGAL INFECTIONS

Ocular fungal infections can affect various parts of the eye, including the cornea (fungal keratitis), conjunctiva, sclera, and intraocular structures, such as the vitreous and aqueous humors (endophthalmitis). These infections are caused by a range of filamentous fungi and yeasts, with the most frequently implicated genera including *Fusarium, Aspergillus*, and *Candida*. *Fusarium* and *Aspergillus* are common in filamentous fungal keratitis, whereas *Candida* species are more commonly involved in endophthalmitis, particularly in immunocompromised patients or those with underlying systemic diseases [4]. Fungal keratitis typically follows ocular trauma, especially in agricultural settings where plant material or soil introduces fungal spores into the corneal tissue. In developed countries, the use of contact lenses especially poor hygiene and prolonged wear is a significant risk factor. Systemic fungal infections, intravenous drug use, post-surgical contamination, and immunosuppressive therapies are leading contributors to intraocular fungal infections. Environmental factors, such as humidity and temperature, significantly influence the incidence of fungal eye diseases, making them more prevalent in tropical and subtropical climates [5].

The pathogenesis begins with the adhesion of fungal spores to the damaged corneal epithelium, followed by germination and hyphal penetration into the deeper stromal layers. Fungal organisms secrete proteolytic enzymes and toxins that degrade host tissues and elicit a robust inflammatory response. The resulting cellular infiltration, neovascularization, and tissue necrosis contribute to corneal opacity and vision impairment. In cases of endophthalmitis, fungal proliferation within the intraocular chambers can lead to panophthalmitis, retinal detachment, and irreversible blindness if left untreated [6]. Epidemiologically, fungal eye infections account for a substantial proportion of microbial keratitis cases in developing countries, with incidence rates as high as 35–50% in some regions. The diagnosis is often delayed due to the indolent nature of fungal infections and the similarity of clinical features with bacterial keratitis. Laboratory confirmation using direct microscopy, culture, PCR, or confocal microscopy is essential for accurate diagnosis and appropriate treatment selection. The limited availability of diagnostic facilities and antifungal susceptibility testing in resource-limited settings further complicates timely and effective management [7].

Understanding the pathophysiology and epidemiology of ocular fungal infections is essential for developing effective therapeutic strategies and drug delivery systems. The challenges associated with timely diagnosis, aggressive progression, and therapeutic resistance underscore the need for localized, sustained-release formulations that can maintain effective drug concentrations at the site of infection. In this regard, ocular films represent a promising intervention that aligns with the physiological and clinical demands of antifungal ocular therapy.

CONVENTIONAL OCULAR DRUG DELIVERY SYSTEMS: LIMITATIONS AND CHALLENGES

Topical eye drops and ointments are the most used delivery systems for ocular antifungal therapy. However, they face significant limitations, such as poor drug solubility, rapid precorneal drug loss due to blinking and tear drainage, and limited corneal permeability. As a result, only a small fraction of the administered drug reaches the target tissue. Frequent dosing is often required to maintain therapeutic drug levels, leading to poor patient adherence. Systemic administration is associated with systemic side effects and limited ocular drug penetration due to the blood-ocular barrier [8–9]. These limitations underscore the need for localized and sustained ocular drug delivery approaches.

OCULAR FILMS: CONCEPT AND DESIGN

Ocular films are thin, polymer-based structures designed to deliver therapeutic agents directly to the ocular surface. They are intended to overcome the limitations of conventional ocular delivery methods by providing sustained and controlled drug release, enhanced ocular bioavailability, and improved patient adherence. These films are generally transparent or semi-transparent and are designed to be non-irritating, mucoadhesive, and capable of withstanding mechanical stresses during blinking [10].

Design of Ocular Films

The design of ocular films is a multifaceted process that involves careful consideration of various physicochemical, mechanical, and biological parameters. An ideal ocular film must possess optimal thickness, tensile strength, flexibility, folding endurance, hydration capacity, and surface pH to ensure compatibility with ocular tissues and prolonged retention on the ocular surface (Figure 1).



Figure 1. Ocular films.

Polymers Used in Film Fabrication

The selection of polymers is crucial in ocular film formulation, as they determine the mechanical strength, drug release behavior, and bioadhesive properties. Commonly used polymers include natural polymers, such as chitosan, gelatin, and alginate; semi-synthetic polymers like hydroxypropyl methylcellulose (HPMC), carboxymethylcellulose (CMC), and methylcellulose (MC); and synthetic polymers, such as polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), and Eudragit derivatives. Blends of these polymers are often employed to achieve the desired film characteristics [11–12].

Formulation and Manufacturing Techniques

Several techniques are employed for the preparation of ocular films, each with specific advantages depending on the intended application.

Solvent Casting Method

This is the most used technique wherein the drug and polymer(s) are dissolved or dispersed in a suitable solvent system, cast onto a flat surface, and dried to form a uniform film. Parameters, such as drying temperature, humidity, and solvent evaporation rate are critical in determining film uniformity and drug distribution [13].

Hot-Melt Extrusion

In this solvent-free technique, the drug-polymer mixture is melted and extruded to form films. It avoids the use of potentially toxic organic solvents and is suitable for thermally stable drugs [14].

Electrospinning

This technique is used to produce nanofibrous films with high surface area and porosity, which can enhance drug loading and controlled release. It is particularly useful for incorporating sensitive bioactives and achieving rapid onset of action [15].

Compression Molding and 3D Printing

These advanced fabrication techniques allow precise control over film geometry and layer-by-layer drug incorporation, offering potential for personalized medicine applications in ocular therapy [16].

Drug Loading and Release Strategies

Drugs can be incorporated into ocular films either by mixing with the polymer matrix (matrix-type films) or by sandwiching them between layers (reservoir-type films). The release of the drug can be modulated by varying polymer type, molecular weight, crosslinking density, and use of plasticizers or pore-forming agents. Multi-layered or bilayered designs enable sequential release of multiple drugs or a combination of immediate and sustained release [17].

Evaluation Parameters

Characterization of ocular films involves the assessment of physical appearance, thickness, folding endurance, tensile strength, swelling index, surface pH, transparency, moisture uptake/loss, and in vitro/in vivo drug release. Mucoadhesion studies, sterility testing, and ocular irritation tests are critical for establishing safety and efficacy. Ex vivo permeation studies using excised cornea or conjunctival tissue and in vivo studies in animal models help validate the therapeutic potential [18].

Incorporation of Advanced Technologies

Innovations, such as nanoparticles, micelles, and liposomes can be embedded within ocular films to enhance drug solubility, stability, and permeability. Smart films that respond to stimuli, such as pH, temperature, or enzymes are also being explored to enable on-demand drug release [19].

MECHANISM OF DRUG RELEASE AND FILM RETENTION

The mechanism of drug release from ocular films primarily depends on the physicochemical properties of the drug and the matrix-forming polymers used in the formulation. Typically, drug release occurs via diffusion, erosion, swelling, or a combination of these processes (Figure 2).



Figure 2. Antifungal drug delivery through ocular film.

Drug Release Mechanism

In matrix-type ocular films, drug molecules are uniformly distributed within the polymer network. Upon contact with the tear fluid, the film undergoes hydration and swelling, allowing the drug to diffuse out of the polymer matrix into the tear film and eventually into the corneal and conjunctival tissues. In some cases, erosion of the polymer matrix contributes to sustained drug release, particularly in biodegradable formulations. Reservoir-type films, on the other hand, offer more controlled and predictable release patterns by enclosing the drug in a core surrounded by a rate-controlling membrane [20].

Diffusion-controlled release is influenced by the molecular size and solubility of the drug, the porosity of the film, and the polymer-drug interactions. Hydrophilic drugs tend to diffuse more readily in hydrophilic polymeric matrices, whereas lipophilic drugs may require additional excipients or encapsulation strategies, such as micelles or nanoparticles for effective release. Swelling-controlled systems are based on the polymer's ability to absorb tear fluid and swell, creating a gel-like barrier that modulates the diffusion rate of the drug. In these systems, the degree of crosslinking and the hydrophilicity of the polymer are critical factors determining the extent and duration of drug release [21].

Mucoadhesion and Film Retention

An essential feature of ocular films is their ability to adhere to the ocular mucosa, which ensures prolonged residence time and localized drug delivery. Mucoadhesion is primarily achieved through non-covalent interactions, such as hydrogen bonding, van der Waals forces, and electrostatic interactions between the film polymer and the mucin layer of the tear film. Polymers, such as chitosan, HPMC, and carbopol are known for their excellent mucoadhesive properties. These polymers interact with mucin glycoproteins on the ocular surface, enhancing the retention of the film even under dynamic conditions, such as blinking and tear flow. This retention not only improves drug bioavailability but also reduces the frequency of administration and enhances patient compliance [22].

Film flexibility, hydration capacity, and surface roughness also play critical roles in determining the extent of mucoadhesion. Excessively rigid or hydrophobic films may result in poor adhesion or ocular discomfort. Therefore, achieving an optimal balance between mechanical strength and surface wettability is vital. Advanced strategies to enhance retention include the incorporation of bioadhesive nanoparticles, use of bilayer or multilayer designs with dedicated mucoadhesive surfaces, and development of in situ gelling films that undergo sol-to-gel transition upon exposure to ocular fluids [23].

ANTIFUNGAL DRUGS INCORPORATED INTO OCULAR FILMS

The incorporation of antifungal agents into ocular films is a promising strategy to achieve localized, sustained drug delivery directly to the site of infection. Antifungal drugs used in these formulations must possess appropriate solubility, stability, and compatibility with film-forming polymers. Common antifungal agents used in ocular films include natamycin, amphotericin B, voriconazole, fluconazole, and itraconazole. These drugs exhibit broad-spectrum antifungal activity against common pathogens like *Aspergillus, Fusarium*, and *Candida species* [24].

Natamycin, a polyene antifungal, is one of the few agents approved specifically for ocular use, particularly in fungal keratitis. However, its low water solubility and limited corneal penetration reduce its efficacy when used as eye drops. Amphotericin B is effective against a wide range of fungi but presents challenges related to its toxicity and poor aqueous solubility. Azole antifungals, such as voriconazole and fluconazole have shown better ocular penetration and are often preferred in film-based delivery systems due to their stability and potent antifungal activity. Incorporating these agents into ocular films can overcome many limitations of conventional formulations. The sustained release provided by the film matrix helps maintain therapeutic drug levels at the infection site over an extended period, reducing the need for frequent dosing and enhancing patient compliance [25]. Furthermore, the direct application of films on the ocular surface minimizes systemic absorption and associated side effects.

Despite these advantages, there is a growing need to improve current ocular film formulations for fungal infections. Fungal pathogens are increasingly developing resistance to standard antifungal treatments, necessitating the development of advanced delivery systems that enhance drug efficacy. Novel approaches, such as co-delivery of antifungals with penetration enhancers, incorporation of bioadhesive and thermoresponsive polymers, and the use of combination therapy with synergistic agents are being explored. Additionally, emerging antifungal agents with improved pharmacological profiles are being evaluated for ocular application through film technology. These include echinocandins and newer triazoles, which offer enhanced activity against resistant fungal strains [26]. Research is also focusing on natural and plant-derived antifungal compounds, which may serve as effective alternatives or adjuncts to synthetic drugs.

ADVANTAGES OF OCULAR FILMS OVER CONVENTIONAL THERAPIES

Ocular films present several distinct advantages over traditional ocular drug delivery systems, such as eye drops, ointments, and suspensions. One of the most significant benefits is the prolonged residence time on the ocular surface, which allows for sustained and controlled drug release. Unlike eye drops, which are rapidly drained away due to tear turnover and blinking, ocular films adhere to the conjunctival or corneal surface, ensuring that the drug remains in contact with the target tissues for an extended period. This prolonged contact enhances the drug's bioavailability, allowing lower doses to achieve therapeutic effects, which reduces the risk of systemic side effects [27–28]. Additionally, ocular films offer the ability to encapsulate a wide range of antifungal agents, including poorly water-soluble compounds, like amphotericin B and itraconazole, which are often ineffective in conventional formulations due to their limited solubility and rapid clearance.

Another major advantage is the improvement in patient compliance. Eye drops often require frequent administration, which can be inconvenient and difficult for patients, particularly those with limited dexterity or chronic conditions. Ocular films, being a once or twice daily application, reduce the treatment burden and enhance adherence to therapy [29]. This is particularly beneficial in managing chronic or stubborn fungal infections, where consistent and prolonged drug exposure is essential for successful outcomes. Moreover, ocular films can be designed for unidirectional drug release, targeting the inner surface of the eyelid or cornea while minimizing drug loss into the surrounding tissues or systemic circulation. This selective delivery increases therapeutic efficiency and minimizes unwanted side effects. Films also eliminate the need for preservatives, which are commonly used in multi-dose eye drop containers and are known to cause irritation and toxicity with prolonged use [30].

Sterility and ease of storage further contribute to the advantages of ocular films. They can be manufactured as single-use sterile units, reducing the risk of contamination and ensuring safe administration. Their solid, compact form makes them more stable under various storage conditions compared to liquid formulations, extending their shelf life and maintaining drug efficacy. In addition, ocular films offer the potential for innovative formulation strategies. Technologies, such as mucoadhesive polymers, multilayer films, and the integration of nanocarriers open new possibilities for enhancing drug delivery and customizing release profiles based on the severity and type of infection [31]. These technologies also allow for the incorporation of diagnostic agents or sensors for monitoring treatment progress, which is not feasible with conventional dosage forms.

CHALLENGES AND FUTURE PROSPECTS

Despite the promising benefits of ocular films, several scientific and technological challenges must be addressed to realize their full potential in the treatment of ocular fungal infections. One major hurdle is achieving optimal drug loading while maintaining the physical integrity and comfort of the film [32]. Many potent antifungal agents have poor aqueous solubility and may require solubilizing agents, co-polymers, or nanocarrier systems to be effectively incorporated into the film matrix without compromising its flexibility or transparency. Formulating films with a uniform and reproducible drug distribution is also a critical challenge, particularly for drugs that are sensitive to environmental factors, such as light, moisture, or temperature. Ensuring the stability of both the drug and the polymeric carrier system during manufacturing and storage is essential for clinical applicability. Furthermore, scale-up processes from lab-scale production to commercial manufacturing require rigorous optimization of casting techniques, drying conditions, sterilization methods, and packaging materials [33].

Biocompatibility and ocular tolerance are another area of concern. The polymers used must not induce irritation, allergic responses, or cytotoxicity upon repeated application. Selecting the appropriate polymer type and concentration is essential to achieve the right balance between mechanical strength, mucoadhesion, and patient comfort. Additionally, variations in tear composition and ocular surface physiology between individuals can influence film performance and drug release, necessitating personalized or adjustable formulations in the future. From a regulatory perspective, the path to approval for ocular films involves comprehensive evaluations of efficacy, safety, and quality [34]. These requirements pose a barrier to rapid clinical translation, especially when novel polymers or nanomaterials are involved. Standardized guidelines specific to ocular film drug delivery are currently limited, which can delay development timelines.

In terms of research directions, prospects include the development of smart ocular films that can respond to stimuli, such as pH, temperature, or enzymatic activity for on-demand drug release. Integrating biosensors or diagnostic elements into the film matrix is another exciting area, enabling real-time monitoring of infection status or drug levels. The use of biodegradable, self-dissolving films that eliminate the need for removal after drug delivery also holds promise [35]. Collaborative research across pharmaceutical technology, material science, and clinical ophthalmology will be crucial in overcoming these challenges. By addressing these scientific hurdles, ocular films can be further refined and positioned as a mainstream, reliable therapeutic modality for the management of ocular fungal infections and beyond.

CONCLUSIONS

Ocular films represent a promising strategy for the treatment of fungal eye infections, offering targeted and sustained drug delivery with improved patient outcomes. Their ability to overcome the limitations of conventional therapies makes them an attractive option for clinical use. Continued research and development are essential to optimize formulations, ensure safety and efficacy, and facilitate the translation of ocular film technology from bench to bedside.

REFERENCES

1. Gote V, Sikder S, Sicotte J, Pal D. Ocular drug delivery: Present innovations and future challenges. J Pharmacol Exp Ther. 2019;370:602–24.

2. Zhang J, Jiao J, Niu M, Gao X, Zhang G, Yu H, et al. Ten years of knowledge of nano-carrier based drug delivery systems in ophthalmology: Current evidence, challenges, and future prospective. Int J Nanomedicine. 2021;16:6497–530.
3. Subrizi A, Del Amo EM, Korzhikov-Vlakh V, Tennikova T, Ruponen M, Urtti A. Design principles of ocular drug delivery systems: Importance of drug payload, release rate, and material properties. Drug Discov Today. 2019;24:1446–57.
4. Klotz SA, Penn CC, Negvesky GJ, Butrus SI. Fungal and parasitic infections of the eye. Clin Microbiol Rev. 2000;13:662–85.
5. Haseeb AA, Elhusseiny AM, Siddiqui MZ, Ahmad KT, Sallam AB. Fungal endophthalmitis: A comprehensive review. J Fungi. 2021;7:996.
6. Thielen TL, Castle SS, Terry JE. Anterior ocular infections: An overview of pathophysiology and treatment. Ann Pharmacother. 2000;34(2):235–46.
7. Miller D. Update on the epidemiology and antibiotic resistance of ocular infections. Middle East Afr J Ophthalmol. 2017;24:30–42.
8. Akhter MH, Ahmad I, Alshahrani MY, Al-Harbi AI, Khalilullah H, Afzal O, et al. Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system. Gels. 2022;8(2):82.
9. Bachu RD, Chowdhury P, Al-Saedi ZHF, Karla PK, Boddu SHS. Ocular drug delivery barriers—Role of nanocarriers in the treatment of anterior segment ocular diseases. Pharmaceutics. 2018; 10:28.
10. Maddileti R, Chinthaginjala H. Precision formulation of ocular films for eye infections using innovative quality by design optimization. Drug Metab Bioanal Lett. 2025. [Forthcoming].
11. Koutsoviti M, Siamidi A, Pavlou P, Vlachou M. Recent advances in the excipients used for modified ocular drug delivery. Materials (Basel). 2021;14(15):4290.
12. Prasad D, Chauhan H. Excipients utilized for ophthalmic drug delivery systems. In: Nano-Biomaterials for Ophthalmic Drug Delivery. Cham: Springer International Publishing; 2016. p. 555–82.
13. Balguri SP, Adelli GR, Tatke A, Janga KY, Bhagav P, Majumdar S. Melt-cast noninvasive ocular inserts for posterior segment drug delivery. J Pharm Sci. 2017;106(12):3515–23.
14. Liu X, Lu M, Guo Z, Huang L, Feng X, Wu C. Improving the chemical stability of amorphous solid dispersion with cocrystal technique by hot melt extrusion. Pharm Res. 2012;29(3):806–17.
15. Krstić M, Radojević M, Stojanović D, Radojević V, Uskoković P, Ibrić S. Formulation and characterization of nanofibers and films with carvedilol prepared by electrospinning and solution casting method. Eur J Pharm Sci. 2017;101:160–6.
16. Alzahrani A, Youssef AAA, Nyavanandi D, Tripathi S, Bandari S, Majumdar S, et al. Design and optimization of ciprofloxacin hydrochloride biodegradable 3D printed ocular inserts: Full factorial design and in-vitro and ex-vivo evaluations: Part II. Int J Pharm. 2023;631:122533.
17. Zhang J, Feng X, Patil H, Tiwari RV, Repka MA. Coupling 3D printing with hot-melt extrusion to produce controlled-release tablets. Int J Pharm. 2017;519:186–97.
18. Khalil IA, Ali IH, El-Sherbiny IM. Noninvasive biodegradable nanoparticles-in-nanofibers single-dose ocular insert: In vitro, ex vivo and in vivo evaluation. Nanomed (Lond). 2019;14(1):33–55.
19. Khan SA, Ma X, Jermain SV, Ali H, Khalil IA, El Fouly M, et al. Sustained release biocompatible ocular insert using hot melt extrusion technology: Fabrication and in-vivo evaluation. J Drug Deliv Sci Technol. 2022;71:103333.
20. Chou SF, Woodrow KA. Relationships between mechanical properties and drug release from electrospun fibers of PCL and PLGA blends. J Mech Behav Biomed Mater. 2017;65:724–33.
21. Kim YC, Chiang B, Wu X, Prausnitz MR. Ocular delivery of macromolecules. J Control Release. 2014;190:172–81.
22. Park CG, Kim YK, Kim SN, Lee SH, Huh BK, Park MA, et al. Enhanced ocular efficacy of topically delivered dorzolamide with nanostructured mucoadhesive microparticles. Int J Pharm. 2017;522:66–73.
23. Yu A, Shi H, Liu H, Bao Z, Dai M, Lin D, et al. Mucoadhesive dexamethasone-glycol chitosan nanoparticles for ophthalmic drug delivery. Int J Pharm. 2020;575:118943.

24. Rapti C, Luciano FC, Anaya BJ, Ramirez BI, Ongoren B, Dea-Ayuela MA, et al. Amphotericin B ocular films for fungal keratitis and a novel 3D-printed microfluidic ocular lens infection model. J Fungi. 2024;10(11):762.
25. Manzouri B, Vafidis GC, Wyse RK. Pharmacotherapy of fungal eye infections. Expert Opin Pharmacother. 2001;2(11):1849–57.
26. Watchaputi K, Jayasekara L, Ratanakhanokchai K, Soontorngun N. Inhibition of cell cycle-dependent hyphal and biofilm formation by a novel cytochalasin 19,20-epoxycytochalasin Q in Candida albicans. Sci Rep. 2023;13:9724.
27. Tighsazzadeh M, Mitchell JC, Boateng JS. Development and evaluation of performance characteristics of timolol-loaded composite ocular films as potential delivery platforms for treatment of glaucoma. Int J Pharm. 2019;566:111–25.
28. Mostafa M, Al Fatease A, Alany RG, Abdelkader H. Recent advances of ocular drug delivery systems: Prominence of ocular implants for chronic eye diseases. Pharmaceutics. 2023;15(6):1746.
29. Bachu RD, Chowdhury P, Al-Saedi ZHF, Karla PK, Boddu SHS. Ocular drug delivery barriers—Role of nanocarriers in the treatment of anterior segment ocular diseases. Pharmaceutics. 2018; 10:28.
30. Hovanesian J, Singh IP, Bauskar A, Vantipalli S, Ozden RG, Goldstein MH. Identifying and addressing common contributors to nonadherence with ophthalmic medical therapy. Curr Opin Ophthalmol. 2023;34:S1–13.
31. Kaushal U, Kaur M, Nagpal M, Bhuyan M, Gounder KP. Nanocarriers based ocular therapeutics: Updates, challenges and future prospectives. Curr Drug Res Rev. 2023;15:15–28.
32. Al Yabhouni SA, Mozumder MS, Hassan N, Mourad AI, Issa MTMA. Nanocarrier-based ocular drug delivery: Challenges, prospects, and the therapeutic landscape in the United Arab Emirates. Int J Pharm. 2024;667(Pt B):124899.
33. Tiwari R, Pandey V, Asati S, Soni V, Jain D. Therapeutic challenges in ocular delivery of lipid-based emulsion. Egypt J Basic Appl Sci. 2018;5:121–9.
34. Garg U, Jain N, Kaul S, Rai VK, Pandey M, Nagaich U, et al. The emerging role of 3D-printing in ocular drug delivery: Challenges, current status, and future prospects. J Drug Deliv Sci Technol. 2022; 76:103798.
35. Lalu L, Tambe V, Pradhan D, Nayak K, Bagchi S, Maheshwari R, et al. Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions. J Control Release. 2017;268:19–39.

